Reneo Pharmaceuticals reels in $95M for genetic disease treatment
December 10, 2020
San Diego-based Reneo Pharmaceuticals has raised a $95 million Series B co-led by Novo Ventures and Abingworth. Founded in 2017, the clinical-stage pharmaceutical company is developing therapies for individuals with genetic mitochondrial diseases. The company was valued at $90 million in May 2019, according to PitchBook data.